Latest news with #Telomir-1
Business Insider
19-07-2025
- Business
- Business Insider
Why Is Telomir Pharmaceuticals Stock (TELO) Up 150% Today?
Telomir Pharmaceuticals (TELO) stock rocketed higher on Friday after the preclinical-stage biotechnology company posted data for Telomir-1. This is a potential cancer treatment in development that is currently in the preclinical stage. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. The big news today is Telomir-1's ability to reverse epigenetic gene silencing in aggressive human prostate cancer cells. This revelation comes from a study of these cells in mice. Telomir Pharmaceuticals noted that Telomir-1 outperformed Paclitaxel and Rapamycin, two cancer treatments, in this study. Telomir Pharmaceuticals CEO Erez Aminov said, 'This study provides novel and direct molecular evidence of Telomir-1's ability to reprogram cancer epigenetics. By potentially restoring the function of key tumor suppressor genes like STAT1, we're not just slowing tumor growth-we're turning the immune system back on.' Telomir Pharmaceuticals Stock Movement Today Telomir Pharmaceuticals stock was up 152.07% on Friday, extending a 5.22% rally from yesterday. Even so, the shares have fallen 70.63% year to date and 67.73% over the past 12 months. Today's rally came with heavy trading, as some 57 million shares changed hands, compared to a three-month daily average of about 381,000 units.
Business Insider
18-07-2025
- Business
- Business Insider
Closing Bell Movers: Netflix slips despite ‘beat and raise' Q2 report
In the early hours of the evening session, U.S. equity futures were broadly higher, continuing the Thursday's regular session gains. With earnings season having started with the influx of bank earnings, a handful of smaller financial institutions also reported positive results, with several making gains in after-hours trading. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Among the most notable earnings reports, however, was from Netflix (NFLX), whose shares slid in postmarket trading despite providing a 'beat and raise' report for the second quarter. Of note, the cocmpany inccreased its FY25 forecast for revenue and free cash flow. Additionally, a report on a potential rail operator deal has sent Norfolk Southern (NSC) and CSX (CSX) flying high. Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGS – Interactive Brokers (IBKR) up 4.7% Independent Bank (INDB) up 2,8% Western Alliance (WAL) up 1% ALSO HIGHER – Telomir Pharmaceuticals (TELO) up 140.5% after data demonstrated that Telomir-1 reversed epigenetic silencing by DNA methylation of the STAT1 gene, a tumor suppressor and immune response regulator, in a dose-dependent manner Blaize Holdings (BZAI) up 75% after announcing its hybrid AI platform will be deployed across Asia in collaboration with Starshine Talen Energy (TLN) up 15.5% after agreeing to acquire Moxie and Guernsey gas-fired plants for $3.5B Norfolk Southern (NSC) and CSX (CSX) up 4.3% and 2.4%, respectively, after the Wall Street Journal reported that Union Pacific (UNP) is considering a deal for the Norfolk Southern Jabil (JBL) up 1.8% after announced a $1B stock repurchase program ALSO LOWER –
Business Insider
18-07-2025
- Health
- Business Insider
Telomir says data show Telomir-1 reversed epigenetic silencing
In a regulatory filing, Telomir Pharmaceuticals (TELO) reported new preclinical results evaluating the effects of its lead candidate, Telomir-1, in a murine xenograft model using PC3 human prostate cancer cells. The data demonstrated that Telomir-1 reversed epigenetic silencing by DNA methylation of the STAT1 gene, a tumor suppressor and immune response regulator, in a dose-dependent manner. STAT1 is frequently silenced in advanced cancers via promoter hypermethylation, disrupting immune detection and apoptotic pathways. In this study, Telomir-1 administered orally daily for 21 days resulted in full reversal of STAT1 hypermethylation in tumor tissue. No such reversal was observed in the Paclitaxel group, and only partial demethylation was observed with Rapamycin In addition to STAT1, Telomir-1 also reduced hypermethylation of TMS1, a pro-apoptotic tumor suppressor commonly silenced in prostate cancer. While PTX and Rapamycin showed comparable or greater effects on TMS1 methylation, Telomir-1 is unique in its ability to modulate both STAT1 and TMS1-two genes that together regulate immune response and apoptosis. Importantly, TMS1 also plays a central role in inflammasome activation, which not only contributes to tumor cell death but also supports the immune system's ability to detect and clear abnormal cells. When TMS1 is hypermethylated, this immune signaling pathway is disrupted-reducing caspase-1 activation and inflammatory cytokine release. This can impair immune surveillance and allow cancer cells to persist undetected. By reducing TMS1 hypermethylation, Telomir-1 may help restore immune recognition and enhance the tumor's sensitivity to both chemotherapy and immunotherapy. Telomere length analysis in PC3 tumor tissue showed no measurable elongation following Telomir-1 administration. This finding is relevant given concerns that telomere-targeting compounds may promote tumor progression through telomere extension in malignant cells. In contrast, Telomir-1 demonstrated selective activity without altering telomere length in this model. Telomir is conducting ongoing research to evaluate Telomir-1 across multiple therapeutic areas, including oncology, Wilson's disease, age-related macular degeneration, autism spectrum disorder, and dysphonia. The company is continuing preclinical development across these programs and plans to announce its initial IND indication at a future date. 'We remain encouraged by the preclinical data and continue to explore Telomir-1's potential across several disease areas. Our team is committed to advancing this program thoughtfully and strategically as we move toward clinical development,' said Erez Aminov, CEO of Telomir. Elevate Your Investing Strategy:
Miami Herald
18-06-2025
- Health
- Miami Herald
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging
Study used cell lines obtained from the Progeria Research Foundation to evaluate Telomir-1's effects on key drivers of accelerated aging MIAMI, FLORIDA / ACCESS Newswire / June 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company focused on reversing biological aging and age-related diseases, today announced compelling new preclinical data showing that its lead candidate, Telomir-1, prevented cellular aging in human progeria cell lines obtained from the Progeria Research Foundation. Progeria, or Hutchinson-Gilford Progeria Syndrome (HGPS), is an ultra-rare pediatric disorder caused by a mutation in the LMNA gene. This mutation results in the production of an abnormal protein called progerin, which drives rapid biological aging in children. There are an estimated 400-500 known cases worldwide, including fewer than 30 children currently living with the disease in the United States. Symptoms typically begin within the first two years of life and include growth failure, joint stiffness, loss of body fat and hair, and severe cardiovascular disease. Children with progeria have an average life expectancy of just 13 to 15 years, with most dying from heart attacks or strokes at a young age. The only FDA-approved therapy for progeria, Zokinvy® (lonafarnib), is a farnesyltransferase inhibitor that has been shown to extend lifespan by an average of 4.3 years. However, Zokinvy does not reverse the underlying disease pathology or halt cardiovascular deterioration, which remains the leading cause of death. No approved therapy restores normal cell function or reverses the biological hallmarks of accelerated aging in progeria, highlighting a significant and urgent unmet medical need. Telomir-1 is designed to regulate intracellular metal ions, reduce oxidative stress, restore mitochondrial function, extend telomere length, reverse muscle loss, and reset age-associated DNA methylation patterns - all of which are critical biological pathways implicated in progeria and broader age-related diseases. In this study, conducted by Smart Assays, Telomir-1 was tested in cells taken directly from a child with HGPS. These cells were obtained from The Progeria Research Foundation ( The study evaluated cell viability, reactive oxygen species (ROS), and intracellular calcium signaling - a marker of mitochondrial dysfunction - under both normal and stress-induced conditions. Key findings include: Improved cell viability: Telomir-1 increased survival in a dose-dependent manner, both under basal conditions and even under stress conditions induced by copper and iron-two metal ions known to accelerate aging by generating oxidative damage and destabilizing DNA and of oxidative stress: Progeria cells exhibited abnormally high levels of reactive oxygen species (ROS), a hallmark of cellular aging. Telomir-1 normalized these levels, both under basal conditions and even when ROS was further elevated by toxic metal of mitochondrial function: Iron-induced calcium overload - a signal of mitochondrial damage and a known feature of HGPS - was significantly reduced with Telomir-1, indicating restored mitochondrial regulation and improved cellular energy balance. These results demonstrate that Telomir-1 directly addresses the core cellular dysfunctions driving disease features in progeria - not only protecting cells from damage but restoring critical biological functions. The fact that these results were observed in actual patient-derived human cells offers strong early validation of Telomir-1's therapeutic potential. "These results provide the strongest evidence to date that Telomir-1 is not only protective but also restorative at the molecular and cellular level," said Dr. Angel, Chief Scientific Advisor of Telomir. "What's especially promising is that the improvements we observed directly target the mechanisms known to drive disease progression in progeria - oxidative stress, metal toxicity, and mitochondrial instability. This level of functional rescue in actual patient-derived cells is highly encouraging as we move toward clinical translation. These studies come as further validation of the very promising results obtained previously in both nematode and zebrafish models of adult progeria." "These findings deepen our conviction that Telomir-1 can be a first-in-class therapeutic platform for rare aging syndromes and broader age-related diseases," said Erez Aminov, CEO of Telomir. "By demonstrating the ability to reverse cellular damage in human progeria cells, Telomir-1 represents a potential breakthrough for children who currently have no real options beyond modestly delaying the inevitable. This work also lays the foundation for broader applications in neurodegeneration, metabolic dysfunction, and systemic aging. The new data also build on previously reported studies in zebrafish and C. elegans nematodes harboring the wrn gene mutation (a model of adult progeria, or Werner syndrome), where Telomir-1 significantly extended lifespan, restored telomere length, reversed muscle degeneration, and normalized molecular age markers. Telomir is currently finalizing IND-enabling studies for Telomir-1 and plans to engage with the U.S. Food and Drug Administration (FDA) to explore regulatory pathways, including the potential for orphan drug designation. The company is evaluating multiple rare disease indications for initial clinical development. Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information Helga Moya info@ 396-6723 SOURCE: Telomir Pharmaceuticals, Inc
Indianapolis Star
18-06-2025
- Health
- Indianapolis Star
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria – an Ultra-Rare Genetic Disorder that Causes Rapid Aging
Study used cell lines obtained from the Progeria Research Foundation to evaluate Telomir-1's effects on key drivers of accelerated aging MIAMI, FLORIDA / ACCESS Newswire Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company focused on reversing biological aging and age-related diseases, today announced compelling new preclinical data showing that its lead candidate, Telomir-1, prevented cellular aging in human progeria cell lines obtained from the Progeria Research Foundation. Progeria, or Hutchinson-Gilford Progeria Syndrome (HGPS), is an ultra-rare pediatric disorder caused by a mutation in the LMNA gene. This mutation results in the production of an abnormal protein called progerin, which drives rapid biological aging in children. There are an estimated 400-500 known cases worldwide, including fewer than 30 children currently living with the disease in the United States. Symptoms typically begin within the first two years of life and include growth failure, joint stiffness, loss of body fat and hair, and severe cardiovascular disease. Children with progeria have an average life expectancy of just 13 to 15 years, with most dying from heart attacks or strokes at a young age. The only FDA-approved therapy for progeria, Zokinvy® (lonafarnib), is a farnesyltransferase inhibitor that has been shown to extend lifespan by an average of 4.3 years. However, Zokinvy does not reverse the underlying disease pathology or halt cardiovascular deterioration, which remains the leading cause of death. No approved therapy restores normal cell function or reverses the biological hallmarks of accelerated aging in progeria, highlighting a significant and urgent unmet medical need. Telomir-1 is designed to regulate intracellular metal ions, reduce oxidative stress, restore mitochondrial function, extend telomere length, reverse muscle loss, and reset age-associated DNA methylation patterns – all of which are critical biological pathways implicated in progeria and broader age-related diseases. In this study, conducted by Smart Assays, Telomir-1 was tested in cells taken directly from a child with HGPS. These cells were obtained from The Progeria Research Foundation ( The study evaluated cell viability, reactive oxygen species (ROS), and intracellular calcium signaling – a marker of mitochondrial dysfunction – under both normal and stress-induced conditions. Key findings include: Improved cell viability: Telomir-1 increased survival in a dose-dependent manner, both under basal conditions and even under stress conditions induced by copper and iron-two metal ions known to accelerate aging by generating oxidative damage and destabilizing DNA and telomeres. Reduction of oxidative stress: Progeria cells exhibited abnormally high levels of reactive oxygen species (ROS), a hallmark of cellular aging. Telomir-1 normalized these levels, both under basal conditions and even when ROS was further elevated by toxic metal exposure. Restoration of mitochondrial function: Iron-induced calcium overload – a signal of mitochondrial damage and a known feature of HGPS – was significantly reduced with Telomir-1, indicating restored mitochondrial regulation and improved cellular energy balance. These results demonstrate that Telomir-1 directly addresses the core cellular dysfunctions driving disease features in progeria – not only protecting cells from damage but restoring critical biological functions. The fact that these results were observed in actual patient-derived human cells offers strong early validation of Telomir-1's therapeutic potential. 'These results provide the strongest evidence to date that Telomir-1 is not only protective but also restorative at the molecular and cellular level,' said Dr. Angel, Chief Scientific Advisor of Telomir. 'What's especially promising is that the improvements we observed directly target the mechanisms known to drive disease progression in progeria – oxidative stress, metal toxicity, and mitochondrial instability. This level of functional rescue in actual patient-derived cells is highly encouraging as we move toward clinical translation. These studies come as further validation of the very promising results obtained previously in both nematode and zebrafish models of adult progeria.' 'These findings deepen our conviction that Telomir-1 can be a first-in-class therapeutic platform for rare aging syndromes and broader age-related diseases,' said Erez Aminov, CEO of Telomir. 'By demonstrating the ability to reverse cellular damage in human progeria cells, Telomir-1 represents a potential breakthrough for children who currently have no real options beyond modestly delaying the inevitable. This work also lays the foundation for broader applications in neurodegeneration, metabolic dysfunction, and systemic aging. The new data also build on previously reported studies in zebrafish and C. elegans nematodes harboring the wrn gene mutation (a model of adult progeria, or Werner syndrome), where Telomir-1 significantly extended lifespan, restored telomere length, reversed muscle degeneration, and normalized molecular age markers. Telomir is currently finalizing IND-enabling studies for Telomir-1 and plans to engage with the U.S. Food and Drug Administration (FDA) to explore regulatory pathways, including the potential for orphan drug designation. The company is evaluating multiple rare disease indications for initial clinical development. Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information SOURCE: Telomir Pharmaceuticals, Inc View the original press release on ACCESS Newswire
